GSK, J&J and Pfiz­er vie for $10B RSV vac­cine mar­ket, with Bavar­i­an Nordic and Mod­er­na hot on their trail

Covid-19 isn’t the on­ly res­pi­ra­to­ry virus wreak­ing hav­oc around the world and push­ing a bevy of drug­mak­ers to in­vest in a vac­cine.

Res­pi­ra­to­ry syn­cy­tial virus …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER